8th Nov 2010 16:53
8 November 2010
Cyprotex PLC
("Cyprotex" or the "Company")
Director dealings
Macclesfield, UK - Cyprotex PLC (LSE: CRX), the preclinical ADME Tox services company, was informed on 21 October 2010 that Ralph Stephen Harris transferred 707,142 ordinary shares of 0.1 pence each out of his total holding of 1,507,142 in the Company ("Ordinary Shares") to his IPS Partnership SIPP. Mr. Harris's beneficial holding remains unchanged at 0.67%of the total issued share capital of the Company.
Enquiries:
Cyprotex PLC | Tel: +44 1625 505 100 |
Dr. Anthony Baxter, Chief Executive Officer | |
www.cyprotex.com | |
Singer Capital Markets Ltd | Tel: +44 203 205 7500 |
Shaun Dobson | |
Claes Spång | |
Financial Dynamics | Tel: +44 207 831 3113 |
Ben Brewerton | |
Ben Atwell | |
Mo Noonan |
Notes to Editors:
Cyprotex PLC
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
www.cyprotex.com
Related Shares:
CRX.L